Gecacitinib Application Scope

Gecacitinib is a dual JAK/ACVR1 inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF), including those with anemia. It has demonstrated efficacy in reducing spleen volume, alleviating symptoms, and improving anemia in clinical trials.

Gecacitinib Characteristics

Ingredients: Gecacitinib hydrochloride (active ingredient)
Properties: Oral solid dosage form; capsules
Packaging Specification: 50 mg × 60 capsules/bottle
Storage: Store in a cool, dry place; protect from light
Expiry Date: 24 months from the date of manufacture
Executive Standard: Conforms to national drug quality standards
Approval Number: H20250023 (example format; refer to local label for specific country code)
Date of Revision: Refer to most recent local prescribing information
Manufacturer: Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Guidelines for the Use of Zepuping

Dosage and Administration:
- Recommended Dose: 100 mg orally once daily
- Administration: Take with or without food; swallow whole; do not chew or crush
- Missed Dose: If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose to make up for a missed dose
Adverse Reactions:
- Common Adverse Reactions: Anemia, thrombocytopenia, neutropenia, leukopenia, diarrhea, nausea, fatigue
- Serious Adverse Reactions: Severe infections, gastrointestinal perforation, thrombosis, hemorrhage
Contraindications:
- Hypersensitivity: Known hypersensitivity to gecacitinib or any excipient
- Pregnancy: Contraindicated during pregnancy; may cause fetal harm
- Lactation: Not recommended during breastfeeding
Precautions:
- Hematologic Monitoring: Regular monitoring of complete blood counts is recommended
- Infection Risk: Monitor for signs of infection; appropriate antimicrobial therapy should be initiated if an infection occurs
- Liver Function: Monitor liver function tests periodically
- Gastrointestinal Perforation: Monitor for signs and symptoms of gastrointestinal perforation
- Thrombosis: Monitor for signs and symptoms of thrombosis

Gecacitinib Interactions

CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase Gecacitinib plasma levels → monitor for toxicity
CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy → avoid or adjust dose
Other myelosuppressive agents – additive hematologic toxicity → monitor CBC
Anticoagulants / Antiplatelets – increased bleeding risk → monitor clinically
Strong P-gp inhibitors – may increase absorption → monitor for adverse effects

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.